Emerging B-Cell Therapies in Systemic Lupus Erythematosus
Ayse Bag-Ozbek,1 Joyce S Hui-Yuen2– 4 1Division of Rheumatology, Renaissance School of Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA; 2Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, New Hyde Park, NY, USA; 3Zucker School of M...
Guardado en:
Autores principales: | Bag-Ozbek A, Hui-Yuen JS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0f39e0e280bd46ca8abcec20e52204ff |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics
por: Xirui Guo, et al.
Publicado: (2021) -
Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care
por: Chessa E, et al.
Publicado: (2017) -
Terapias biológicas en el lupus eritematoso sistémico
por: CAIROLI,ERNESTO, et al.
Publicado: (2010) -
Association Between the Interferon-γ +874 T/A Polymorphism and the Risk and Clinical Manifestations of Systemic Lupus Erythematosus: A Preliminary Study
por: Liu S, et al.
Publicado: (2021) -
Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
por: Sabugo S,Francisca, et al.
Publicado: (2005)